Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 446 results found since Jan 2013.
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
CONCLUSION: As first-line agents, SGLT2 inhibitors and GLP1 receptor agonists would improve type 2 diabetes outcomes, but their costs would need to fall by at least 70% to be cost-effective.PRIMARY FUNDING SOURCE: American Diabetes Association.PMID:36191315 | DOI:10.7326/M21-2941
Source: Annals of Internal Medicine - October 3, 2022 Category: Internal Medicine Authors: Jin G Choi Aaron N Winn M Reza Skandari Melissa I Franco Erin M Staab Jason Alexander Wen Wan Mengqi Zhu Elbert S Huang Louis Philipson Neda Laiteerapong Source Type: research
Vascular phenotype at 35-37 weeks' gestation in women with gestational diabetes mellitus
CONCLUSION: Women with GDM have evidence of early vascular disease and this may contribute to their long-term cardiovascular risk. This article is protected by copyright. All rights reserved.PMID:36173400 | DOI:10.1002/uog.26077
Source: The Ultrasound Review of Obstetrics and Gynecology - September 29, 2022 Category: Radiology Authors: T Mansukhani A Arechvo F Cecchini M Breim A Wright K H Nicolaides M Charakida Source Type: research
Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research
Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus
Diabetes mellitus is a well-known risk factor for ischemic stroke and is associated with unfavorable outcome after stroke. Metformin is recommended as first-line treatment in these patients. Pre-stroke metformin use might have neuroprotective properties resulting in reduced stroke severity. However, results of the effects of pre-stroke metformin use on functional outcome are conflicting and has not been previously described in patients with type 2 diabetes mellitus regardless of stroke severity or revascularization treatment.
Source: Journal of Stroke and Cerebrovascular Diseases - August 1, 2022 Category: Neurology Authors: C.J.B.A. Kersten, I.L.H. Knottnerus, E. Heijmans, M. Haalboom, A.A.M. Zandbergen, H.M. den Hertog Source Type: research
People With Diabetes Are More Vulnerable to Heart Disease. How to Reduce the Risk
If you’ve been diagnosed with diabetes, know that you’ve got plenty of company. The American Diabetes Association (ADA) reports that in 2019, the most recent year for which data is available, 37.3 million adults in the U.S.—about 11.3% of the population—had the chronic condition, and that number continues to grow.
Type 1 diabetes develops when the body isn’t able to produce insulin, and Type 2 occurs when the body doesn’t use insulin correctly. Type 2 is the most common form of diabetes, and when it’s uncontrolled, a person’s blood sugar can jump to dangerous levels that requ...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Elaine K. Howley Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Metformin Alleviates Delayed Hydrocephalus after Intraventricular Hemorrhage by Inhibiting Inflammation and Fibrosis
In conclusion, metformin attenuated neuroinflammation and subsequent fibrosis after IVH by regulating AMPK /SIRT1/ NF-κB pathways, thereby reducing delayed hydrocephalus. Metformin may be a promising therapeutic agent to prevent delayed hydrocephalus following IVH.PMID:35852765 | DOI:10.1007/s12975-022-01026-3
Source: Cell Research - July 19, 2022 Category: Cytology Authors: Yi Cao Chang Liu Gaowei Li Weina Gao Hui Tang Shuanmin Fan Xin Tang Long Zhao Haoxiang Wang Aijun Peng Chao You Aiping Tong Liangxue Zhou Source Type: research
The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke
CONCLUSION: The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size.PMID:35792967 | DOI:10.1007/s43440-022-00382-z
Source: Pharmacological Reports - July 6, 2022 Category: Drugs & Pharmacology Authors: Rashmi Kumari Lisa Willing Scot R Kimball Ian A Simpson Source Type: research
Development and Evaluation of Novel Metformin Derivative Metformin Threonate for Brain Ischemia Treatment
Epidemiologic data reveal that diabetes patients taking metformin exhibit lower incidence of stroke and better functional outcomes during post-stroke neurologic recovery. We previously demonstrated that chronic post-ischemic administration of metformin improved functional recovery in experimental cerebral ischemia. However, few beneficial effects of metformin on the acute phase of cerebral ischemia were reported either in experimental animals or in stroke patients, which limits the application of metformin in stroke. We hypothesized that slow cellular uptake of metformin hydrochloride may contribute to the lack of efficacy...
Source: Frontiers in Pharmacology - June 21, 2022 Category: Drugs & Pharmacology Source Type: research
SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes? SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes?
Real-world study finds heart failure hospitalization reduction compared to metformin but not MI, stroke, or overall mortality, and greater genital infection risk.Medscape Medical News
Source: Medscape Cardiology Headlines - May 23, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed.
The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar...
Source: MedPage Today Cardiovascular - May 23, 2022 Category: Cardiology Source Type: news
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research
